Half-Year 2022 Financial and Clinical Trials Update

HY 2022: Royalties and other operating income Higher income mainly driven by Ultomiris patent settlement CHFM 1,420 -43 +687 +25 -146 Royalties and other operating income increased by +38% at CER HY 2021 Royalty income CER Constant Exchange Rates Out-licensing Income (incl. Ultomiris) 1,943 Other operating income Income from disp. of products HY 2022 Roche 56 56

View entire presentation